Latest news with #MoleMobile
CTV News
3 days ago
- General
- CTV News
Mole van stops in Calgary to offer melanoma screenings
Mole Mobile, which offers free skin exams, is in Calgary this weekend as part of Melanoma Canada's tour of Alberta to educate people about skin care. A mobile van offering free skin exams arrived in Calgary Saturday. Melanoma Canada's Mole Mobile rolled into Calgary this weekend to offer free (for Canadian residents) skin exams, or simply to provide a bit of education about how to care for your skin with summer upon us. The initiative is to educate and facilitate skin care for people, explained Dr. Elaine Dupuis, who was on hand at the Sav-On Foods at Walden Gate S.E. Saturday. 'Skin cancer, when caught early, it is something that is that is very easily managed and has a good prognosis,' said Dr. Dupuis. 'However, if skin cancer is left undetected, it can often spread to other areas, and then that can be a problem, and it can even cause death. 'The fact that skin cancer is visible there on the skin makes detection a bit easier,' she added, 'and so it's important that people have that education about what signs and symptoms to look for on their skin.' Tests are free for Canadian residents. Alberta health cards aren't necessary. Walk-ins are accepted but Melanoma Canada recommends you sign up. The waiting room is outside the mobile, so dress for the weather. The Mole Mobile is at the Sav-On Foods at 420 Na'a Plaza S.W. until 4 p.m. Sunday. Next Sunday, June 8, it will be at the Sav-On Foods in Didsbury between 10 a.m. and 4 p.m., in Brooks on June 13 and Drumheller on June 15. For more information, go here.
CTV News
24-05-2025
- Health
- CTV News
Mobile skin cancer screening unit stopping by this weekend
'Mole Mobile' is a free skin cancer screening clinic that is run by volunteer dermatologists and is travelling across Canada. Oct. 27/23 (Amanda Hicks/CTV Northern Ontario)
CTV News
23-05-2025
- Health
- CTV News
Mobile mole check truck visits Barrie and Orillia
A dermatologist checks moles on a person's back in this undated file image. 'You should have that mole checked.' If you've heard that line before, Saturday or Sunday might be the day to quell those fears. Across Canada, May is Melanoma Awareness Month. Melanoma and skin cancer are one of the few cancers on the rise in Canada and worldwide. In 2016, CDC Statistics reported that incidence rates for new melanoma cases have been rising on average by 1.4% each year over the last ten years. One in three cancers diagnosed is skin cancer. Skin cancers are the most common type of cancer diagnosed in men over 49 years of age and are among the most common cancers diagnosed in youth and young adults. If detected, early melanoma and skin cancers are largely treatable Both Barrie and Orillia are scheduled to have two dermatologists visits on Saturday and Sunday respectively, to check attendees' moles at no charge. A Mole Mobile will make its tour stop on Saturday at Century 21 B.J. Roth Realty - 355 Bayfield Street in Barrie from 10 a.m. to 4 p.m. and Sunday, May 25 at Century 21 B.J. Roth Realty at 450 West Street North in Orillia from 10 a.m. to 4 p.m. The skin checks are open to the public and no appointment is required.
Hamilton Spectator
20-05-2025
- Health
- Hamilton Spectator
REPEAT: Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia ●Rocket Doctor has partnered with Melanoma Canada to provide timely follow-up care for patients identified as at-risk during mobile skin cancer screenings. ●Patients without a family doctor will be directly referred to physicians on Rocket Doctor through a streamlined digital intake process. ●The Mole Mobile campaign travels across Alberta, British Columbia, Ontario, and Quebec, providing free screenings in both remote and urban communities. ● Skin cancer is the most common cancer in Canada, with 1 in 3 cancer diagnoses being skin-related — more than breast, prostate, lung, and colon cancers combined. ● 22 Canadians are diagnosed with melanoma every day, and 3 Canadians die daily from this serious form of skin cancer. ●The partnership is expected to increase patient visits on Rocket Doctor's platform, improving access to care and continuity for at-risk individuals. Toronto, ON, May 20, 2025 (GLOBE NEWSWIRE) — AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is proud to announce that its virtual care subsidiary, Rocket Doctor Inc., has partnered with Melanoma Canada to help bridge the care gap for individuals identified as at-risk for melanoma and other skin cancers during mobile screening events across the country. Melanoma Canada's Mole Mobile units, Canada's first mobile skin cancer screening clinics, presented by Neutrogena®, a Kenvue brand travel across Alberta, British Columbia, Ontario, and Quebec, offering free skin checks from certified dermatologists in both remote and urban communities. Through this partnership, Rocket Doctor will provide patients who do not have a family physician with timely access to follow-up appointments via its virtual care platform. 'Too many Canadians are going without the care they need simply because they don't have a family doctor,' said Dr. William Cherniak, Founder and CEO of Rocket Doctor. 'By partnering with Melanoma Canada, we're making it easier for patients identified during these critical screenings to get connected to a physician quickly, ensuring no one falls through the cracks.' Dermatologists working in the Mole Mobile units will complete an on-site risk assessment and referral form for patients who require follow-up. These forms can then be uploaded directly to Rocket Doctor's intake system, enabling efficient, streamlined review and timely access to appropriate care. The need for follow-up care has never been more urgent. Skin cancer is the most commonly diagnosed cancer in Canada, more prevalent than breast, prostate, lung, and colon cancers combined. One in every three cancers diagnosed in Canada is a skin cancer, and the incidence of melanoma, the deadliest form, continues to rise. Every day, 22 Canadians are diagnosed with melanoma, and 3 die from it. 'With one in three cancers diagnosed in Canada being skin cancer, access to timely follow-up care is crucial,' said Falyn Katz, CEO of Melanoma Canada. 'Our partnership with Rocket Doctor ensures that individuals flagged during our screenings, many of whom don't have a family doctor, can seamlessly transition from screening to care. It's a powerful step forward in improving outcomes for patients who might otherwise be left waiting.' The initiative is expected to increase patient traffic across Rocket Doctor's platform during Mole Mobile's national tour, while reinforcing Rocket Doctor's mission to improve equitable access to physician-led care. As part of the collaboration, Rocket Doctor's logo will also appear on Mole Mobile vans and campaign materials, which collectively generate millions of impressions throughout the tour. The term of this Agreement is 12 months commencing February 3, 2025, and will automatically renew for successive 12-month periods unless either party provides at least 30 days' written notice of termination prior to the renewal date. Initial events will kick off in Toronto and Edmonton this spring, with additional stops planned through October 2025. About Rocket Doctor Inc. Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like. Visit or contact media@ . About Melanoma Canada Melanoma Canada is a national organization dedicated to raising awareness, advancing prevention, and supporting patients affected by melanoma and skin cancer. Through programs like the Mole Mobile, Canada's first mobile skin cancer screening initiative, Melanoma Canada brings early detection, education, and hope to communities across the country. In partnership with Canadian dermatologists, the Mole Mobile has screened thousands of individuals and identified hundreds of potential skin cancers. Learn more at . About AI Inc. AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. Learn more at or contact info@ . FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO Email: ehamza@ Media inquiries: media@ Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements that are based on AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
Hamilton Spectator
20-05-2025
- Health
- Hamilton Spectator
Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia ●Rocket Doctor has partnered with Melanoma Canada to provide timely follow-up care for patients identified as at-risk during mobile skin cancer screenings. ●Patients without a family doctor will be directly referred to physicians on Rocket Doctor through a streamlined digital intake process. ●The Mole Mobile campaign travels across Alberta, British Columbia, Ontario, and Quebec, providing free screenings in both remote and urban communities. ● Skin cancer is the most common cancer in Canada, with 1 in 3 cancer diagnoses being skin-related — more than breast, prostate, lung, and colon cancers combined. ● 22 Canadians are diagnosed with melanoma every day, and 3 Canadians die daily from this serious form of skin cancer. ●The partnership is expected to increase patient visits on Rocket Doctor's platform, improving access to care and continuity for at-risk individuals. Toronto, ON, May 20, 2025 (GLOBE NEWSWIRE) — AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) ('Treatment') is proud to announce that its virtual care subsidiary, Rocket Doctor Inc., has partnered with Melanoma Canada to help bridge the care gap for individuals identified as at-risk for melanoma and other skin cancers during mobile screening events across the country. Melanoma Canada's Mole Mobile units, Canada's first mobile skin cancer screening clinics, presented by Neutrogena®, a Kenvue brand travel across Alberta, British Columbia, Ontario, and Quebec, offering free skin checks from certified dermatologists in both remote and urban communities. Through this partnership, Rocket Doctor will provide patients who do not have a family physician with timely access to follow-up appointments via its virtual care platform. 'Too many Canadians are going without the care they need simply because they don't have a family doctor,' said Dr. William Cherniak, Founder and CEO of Rocket Doctor. 'By partnering with Melanoma Canada, we're making it easier for patients identified during these critical screenings to get connected to a physician quickly, ensuring no one falls through the cracks.' Dermatologists working in the Mole Mobile units will complete an on-site risk assessment and referral form for patients who require follow-up. These forms can then be uploaded directly to Rocket Doctor's intake system, enabling efficient, streamlined review and timely access to appropriate care. The need for follow-up care has never been more urgent. Skin cancer is the most commonly diagnosed cancer in Canada, more prevalent than breast, prostate, lung, and colon cancers combined. One in every three cancers diagnosed in Canada is a skin cancer, and the incidence of melanoma, the deadliest form, continues to rise. Every day, 22 Canadians are diagnosed with melanoma, and 3 die from it. 'With one in three cancers diagnosed in Canada being skin cancer, access to timely follow-up care is crucial,' said Falyn Katz, CEO of Melanoma Canada. 'Our partnership with Rocket Doctor ensures that individuals flagged during our screenings, many of whom don't have a family doctor, can seamlessly transition from screening to care. It's a powerful step forward in improving outcomes for patients who might otherwise be left waiting.' The initiative is expected to increase patient traffic across Rocket Doctor's platform during Mole Mobile's national tour, while reinforcing Rocket Doctor's mission to improve equitable access to physician-led care. As part of the collaboration, Rocket Doctor's logo will also appear on Mole Mobile vans and campaign materials, which collectively generate millions of impressions throughout the tour. The term of this Agreement is 12 months commencing February 3, 2025, and will automatically renew for successive 12-month periods unless either party provides at least 30 days' written notice of termination prior to the renewal date. Initial events will kick off in Toronto and Edmonton this spring, with additional stops planned through October 2025. About Rocket Doctor Inc. Rocket Doctor is a technology-driven digital health platform and marketplace that empowers doctors to build and manage their own virtual or hybrid practices. Its proprietary software and AI-powered tools enable providers to deliver high-quality care remotely, with a focus on reaching underserved and remote communities across North America. By removing barriers to care and restoring physician autonomy, Rocket Doctor is redefining what modern healthcare looks like. Visit or contact media@ . About Melanoma Canada Melanoma Canada is a national organization dedicated to raising awareness, advancing prevention, and supporting patients affected by melanoma and skin cancer. Through programs like the Mole Mobile, Canada's first mobile skin cancer screening initiative, Melanoma Canada brings early detection, education, and hope to communities across the country. In partnership with Canadian dermatologists, the Mole Mobile has screened thousands of individuals and identified hundreds of potential skin cancers. Learn more at . About AI Inc. AI is a company utilizing AI (artificial intelligence) and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, AI has built a comprehensive, personalized healthcare AI engine — the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals as well as providing recommended tests (physical and lab), imaging and billing codes. The GLM helps healthcare professionals (doctors, nurses or pharmacists) reduce their administrative burden; creates more time for needed face-to-face patient appointments; and enables greater consistency in quality of patient support. AI's GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. Learn more at or contact info@ . FOR ADDITIONAL INFORMATION, CONTACT: Dr. Essam Hamza, CEO Email: ehamza@ Media inquiries: media@ Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955 Cautionary Statement This news release contains forward-looking statements that are based on AI's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
